Moteur de recherche d’entreprises européennes
Financement de l’UE (3 870 584 €) : Programme européen de formation à la recherche sur le glaucome-Plus Hor 27/08/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Programme européen de formation à la recherche sur le glaucome-Plus
Glaucoma is the most common age-related neurodegenerative eye-disease in western society and one of the four major blinding eye diseases. If untreated or detected too late, glaucoma will end in blindness, yielding a profound loss of quality of life for the individual and major costs to society. Given the vast complexity of glaucoma, to advance assessment and therapy beyond the current state-of-the-art, we need a new generation of researchers who are deeply knowledgeable about and intimately familiar with the many different approaches for study all aspects of glaucoma and the aging visual system: from functional test to anatomy, from gene to ganglion cell, from retina to brain. However, current knowledge is fragmented and so is the corresponding training. Very few researchers have been adequately trained which severely limits progress. Well-trained teams of dedicated glaucoma researchers are pivotal to integrate and extend the highly specialized knowledge, and to make a real difference for the patient. To overcome this problem, EGRET+ – the European Glaucoma Research Training Program Plus– has the aim of teaching young researchers in how to a) acquire new, quantitative knowledge on glaucoma and the aging visual system, and b) apply this new knowledge to boost innovation in glaucoma care in both the public and private sectors. This will: 1) enable the development of new tools for the early detection and cost-effective monitoring of glaucoma; 2) inspire the development and implementation of new treatments; 3) contribute to our understanding of the relationships between various neurodegenerative diseases, and 4) contribute to improving healthy aging in general. This new knowledge therefore has tremendous potential to positively impact the lives of millions of European citizens.
| AMO Groningen B.V. | ? |
| Academisch Medisch Centrum BIJ DE Universiteit Van Amsterdam | 255 374 € |
| Academisch Ziekenhuis Groningen | 1 276 871 € |
| City St Georges University of London | 546 576 € |
| Echodia | 262 876 € |
| Implandata Ophtalmic Products GmbH | 249 216 € |
| Ocuspecto Oy | 269 145 € |
| Otto-VON-Guericke-Universitaet Magdeburg | 747 649 € |
| Universite Clermont Auvergne | 262 876 € |
https://cordis.europa.eu/project/id/675033
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : AMO Groningen B.V., Groningen, Pays-Bas.